Transforming
Treatment of Severe
Blood Disorders

learn more »

Committed to Serving Patients and Their Families

learn more »

About GBT

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.

more »

Innovative Science

We are passionate and committed to developing new therapies that can provide transformative clinical benefit to patients. Our late-stage product candidate voxelotor (GBT440) is an oral, once-daily therapy that is designed to modulate hemoglobin affinity for oxygen and is in clinical development for the treatment of sickle cell disease.

more »